I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market

Upcoming Product Launches in Adoptive Cell Therapy Segment Hold Future Growth Potential

This study explores the global immuno-oncology (I-O) market’s evolution from 2020 to 2025. An extensive analysis is provided on the growth opportunities envisioned by the analyst to help stakeholders leverage their momentum and disrupt the market by offering best-in-class solutions.

The study considers oncology agents for which the immune system is the basis of their actions, including monoclonal antibodies, cell and gene therapies, bioengineered vaccines, recombinant products, small molecules, and oncolytic viruses. Classified into 5 major therapy types - immunomodulators, adoptive cell therapy, cancer vaccine, oncolytic virus, and antibody-based targeted therapies - the analysis provides revenue forecasts by the global market and product category. The agents are classified into various therapy types based on the mechanism of action (MOA). Concerning pipeline products, we have considered industry-sponsored products under development.

The oncology therapeutic segment is expected to witness minimal impact from the COVID-19 pandemic because of the criticality of treating cancer patients and the segment’s role as a major revenue-generator for pharmaceutical companies. The analyst have considered the impact of COVID-19 and two scenarios for the sales forecast: original scenario and COVID-19 impact scenario.

In the original scenario, the I-O market is expected to reach $132.66 billion by 2025 growing at a rate of 11.6% and witness minimal impact from the COVID-19 pandemic, with 2020 accounting for the majority of the decline. After 2022, the market will positively recuperate and experience a slight increase in revenue due to rebounding R&D budgets and accelerated developments of late-stage clinical candidates.

Research Highlights

Major Themes Covered in This Study:

• Strategic imperatives and key findings
• Overview of I-O market, including the journey from bench to bedside, the value chain and stakeholder ecosystem, R&D expenditure, funding, and investment
• Clinical trial overview for all therapies in consideration, with details for each I-O target and agent
• Regulatory and reimbursement scenario, including risk-sharing models
• Key marketed and pipeline products, market and technology dashboard
• Extensive growth opportunity analysis with metrics, drivers, restraints, and competitive environment
• Market revenue forecast and share analysis for each product segment
• Calls to action aligned with the recommended growth opportunities
• Key company profiles